Document Detail

Current options for drug delivery to the spinal cord.
MedLine Citation:
PMID:  23289716     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Spinal cord disorders (SCDs) are among the most devastating neurological diseases, due to their acute and long-term health consequences, the reduced quality of life and the high economic impact on society. Here, drug administration is severely limited by the blood-spinal cord barrier (BSCB) that impedes to reach the cord from the bloodstream. So, developing a suitable delivery route is mandatory to increase medical chances.
AREAS COVERED: This review provides an overview of drug delivery systems used to overcome the inaccessibility of the cord. On one side, intrathecal administration, either with catheters or with biomaterials, represents the main route to administer drugs to the spinal cord; on the other side, more recent strategies involve chemical or electromagnetic disruption of the barrier and synthesis of novel functionalized compounds as nanoparticles and liposomes able to cross BSCB.
EXPERT OPINION: Both the multifactorial pathological progression and the restricted access of therapeutic drugs to the spine are probably the main reasons behind the absence of efficient therapeutic approaches for SCDs. Hence, very recent highlights suggest the use of original strategies to overcome the BSCB, and new multidrug delivery systems capable of local controlled release of therapeutic agents have been developed. These issues can be addressed by using nanoparticles technology and smart hydrogel drug delivery systems, providing an increased therapeutic compound delivery in the spinal cord environment and multiple administrations able to synergize treatment efficacy.
Filippo Rossi; Giuseppe Perale; Simonetta Papa; Gianluigi Forloni; Pietro Veglianese
Related Documents :
23519656 - Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate...
17580006 - Use of the newer antiepileptic drugs in pediatric epilepsies.
23302696 - Structure and inhibition of the drug-resistant s31n mutant of the m2 ion channel of inf...
16499746 - Influence of lamotrigine and topiramate on mdr1 expression in difficult-to-treat tempor...
24073676 - Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazid...
17133086 - The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemopreve...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-06
Journal Detail:
Title:  Expert opinion on drug delivery     Volume:  10     ISSN:  1744-7593     ISO Abbreviation:  Expert Opin Drug Deliv     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-15     Completed Date:  2013-05-20     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228421     Medline TA:  Expert Opin Drug Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  385-96     Citation Subset:  IM    
Dipartimento di Neuroscienze, Istituto di Ricerche Farmacologiche Mario Negri, via La Masa 19, 20156 Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Delivery Systems*
Liposomes / chemistry
Microcirculation / drug effects
Nanoparticles / chemistry
Neuroprotective Agents / administration & dosage*,  therapeutic use
Regional Blood Flow / physiology
Spinal Cord / blood supply
Spinal Cord Diseases / drug therapy*
Reg. No./Substance:
0/Liposomes; 0/Neuroprotective Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spatial organization of lipid phases in micro-patterned polymer-supported membranes.
Next Document:  A diverse array of genetic factors contribute to the pathogenesis of Systemic Lupus Erythematosus.